Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables
- PMID: 1765572
Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables
Erratum in
- J Clin Psychopharmacol 1992 Apr;12(2):78
Abstract
Fifty-nine plasma thiothixene concentrations were measured in 42 patients as part of routine therapeutic drug monitoring. Data collection included concomitant medications, smoking history, and demographic variables. A retrospective analysis was performed to assess the effect of these parameters on oral thiothixene clearance. When groups of patients were categorized by concomitant medications (i.e., no interacting drugs, enzyme/clearance inducers, and enzyme/clearance inhibitors), thiothixene clearance was found to be significantly increased by enzyme inducing drugs (e.g., anticonvulsants) and decreased by clearance inhibiting agents (e.g., cimetidine). Tobacco smoking significantly increased the hepatic clearance of thiothixene within the no interactions and inhibitor groups, but not in the inducer group. Significantly more patients in the inducer group had nondetectable plasma concentrations of thiothixene than the other groups. When the entire patient population was dichotomized by age, patients less than 50 years old had a significantly greater mean clearance (48.2 +/- 37.8 liters/min) versus those greater than or equal to 50 (20.0 +/- 12.6 liters/min). Men in this cohort exhibited a significantly higher clearance (49.2 +/- 38.7 liters/min) than did the women (22.0 +/- 13.5 liters/min). By taking into account these potential sources of pharmacokinetic variability when monitoring plasma thiothixene concentrations, more appropriate dosing of thiothixene may be achieved. Controlled, prospective studies are needed to validate these findings.
Similar articles
-
The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data.Epilepsy Res. 2006 Aug;70(2-3):153-60. doi: 10.1016/j.eplepsyres.2006.04.002. Epub 2006 May 30. Epilepsy Res. 2006. PMID: 16730950
-
Intramuscular thiothixene in acute psychotic states.N Z Med J. 1980 Dec 24;92(674):459-61. N Z Med J. 1980. PMID: 6937789
-
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.Clin Ther. 2006 Jan;28(1):55-72. doi: 10.1016/j.clinthera.2006.01.015. Clin Ther. 2006. PMID: 16490580 Clinical Trial.
-
Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.Epilepsia. 2008 Jul;49(7):1123-41. doi: 10.1111/j.1528-1167.2008.01665.x. Epilepsia. 2008. PMID: 18503564
-
Development and pharmacology of fluvastatin.Br J Clin Pract Suppl. 1996 Jan;77A:11-5. Br J Clin Pract Suppl. 1996. PMID: 8729584 Review.
Cited by
-
A retrospective cohort study of the prevalence of anxiety and agitation in schizophrenic smokers and the unmet needs of smoking cessation programs.Medicine (Baltimore). 2019 Oct;98(40):e17375. doi: 10.1097/MD.0000000000017375. Medicine (Baltimore). 2019. PMID: 31577741 Free PMC article.
-
Clinical pharmacokinetics of mirtazapine.Clin Pharmacokinet. 2000 Jun;38(6):461-74. doi: 10.2165/00003088-200038060-00001. Clin Pharmacokinet. 2000. PMID: 10885584 Review.
-
In vitro analysis of factors influencing CYP1A2 expression as potential determinants of interindividual variation.Pharmacol Res Perspect. 2017 Mar 2;5(2):e00299. doi: 10.1002/prp2.299. eCollection 2017 Apr. Pharmacol Res Perspect. 2017. PMID: 28357125 Free PMC article.
-
Sex and age differences in the pharmacokinetics of alosetron.Br J Clin Pharmacol. 2002 Mar;53(3):238-42. doi: 10.1046/j.0306-5251.2001.01565.x. Br J Clin Pharmacol. 2002. PMID: 11874386 Free PMC article. Clinical Trial.
-
Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.Schizophr Res Treatment. 2012;2012:407171. doi: 10.1155/2012/407171. Epub 2012 Feb 15. Schizophr Res Treatment. 2012. PMID: 22966436 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical